Dig Inn vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthy fast-casual restaurant chain | NYC-based expansion | Farm-to-table positioning | Nutritionally-focused bowls and salads | Growing consumer health demand
About
Dig — originally Dig Inn — was founded in 2011 in New York City by Adam Eskin to make vegetable-forward, farm-sourced fast casual food accessible to urban workers. The concept is built around seasonal menus designed by a chef team, with whole vegetables and grains as primary ingredients and meat treated as a secondary component. Dig sources directly from regional farms and publishes sourcing relationships on its menu boards, a transparency stance unusual for the fast casual category.\n\nDig's menu is organized around build-your-own plates with a rotating selection of market vegetables, proteins (chicken thighs, salmon, meatballs), and grain bases (farro, rice, lentils) that change with the seasons. Open kitchens make scratch cooking visible to diners, reinforcing fresh-preparation positioning. Dig also operates Dig Acres, a working farm in upstate New York that feeds directly into restaurant supply chains and serves as proof of its farm-to-table sourcing claims.\n\nDig operates approximately 30 locations concentrated in New York City, with restaurants in Philadelphia and Boston targeting urban office markets with high lunch traffic. The brand navigated significant headwinds from pandemic-driven collapse in office lunch demand. As return-to-office patterns stabilize, Dig's positioning — nutritionally dense, seasonal, vegetable-forward fast casual — aligns with durable consumer trends toward health-conscious weekday eating and reduced meat consumption.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.